Press releases Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Mar 28, 2026 Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Mar 20, 2026 Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting Mar 12, 2026 Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Mar 06, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 26, 2026 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets Feb 24, 2026 Nektar Therapeutics to Participate in Two Investor Conferences in March Feb 17, 2026 Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis Feb 13, 2026 Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Feb 11, 2026 Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering Feb 10, 2026 Nektar Therapeutics Announces Proposed Public Offering Contact IR Print Page RSS Email Alerts
Nektar in the news Items Per Page 102550 News Category AllFinancialGeneral Year All202620252024202320222021202020192018201720162015201420132012201120102009200820072006 Mar 28, 2026 Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting Mar 20, 2026 Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting Mar 12, 2026 Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Mar 06, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 26, 2026 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets Feb 24, 2026 Nektar Therapeutics to Participate in Two Investor Conferences in March Feb 17, 2026 Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis Feb 13, 2026 Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares Feb 11, 2026 Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering Feb 10, 2026 Nektar Therapeutics Announces Proposed Public Offering
Mar 28, 2026 Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Mar 20, 2026 Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Feb 26, 2026 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Feb 17, 2026 Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Feb 13, 2026 Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
